Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system

Journal of Clinical Lipidology

Volumn 11, Issue 1, 2017, Pages 70-79.e1

  Graham, Jove H ^a   Sanchez, Robert J ^b   Saseen, Joseph J ^c   Mallya, Usha G ^d   Panaccio, Mary P ^d   Evans, Michael A ^a  

^a GEISINGER HEALTH SYSTEM   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d SANOFI   (France)

Author keywords

Health care costs; High CV risk; Integrated health system; LDL C; Statin intolerance

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ECONOMIC ASPECT; ELECTRONIC HEALTH RECORD; FEMALE; GOAL ATTAINMENT; HEALTH CARE COST; HUMAN; INTEGRATED HEALTH CARE SYSTEM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; UNITED STATES; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COHORT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; COHORT STUDIES; DELIVERY OF HEALTH CARE; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85006091186     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.10.003     Document Type: Article

References (52)

1. 1 Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al., IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372 (2015), 2387–2397.
2. 2 Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
3. 3 Cholesterol Treatment Trialists' (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
4. 4 Taylor, F., Huffman, M.D., Macedo, A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev(1), 2013, CD004816.
5. 5 Anderson, T.J., Grégoire, J., Hegele, R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29 (2013), 151–167.
6. 6 European Association for Cardiovascular Prevention & Rehabilitation, Reiner, Z., Catapano, A.L., De Backer, G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 (2011), 1769–1818.
7. 7 Stroes, E.S., Thompson, P.D., Corsini, A., et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 36 (2015), 1012–1022.
8. 8 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
9. 9 Teramoto, T., Sasaki, J., Ishibashi, S., et al. Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. J Atheroscler Thromb 20 (2013), 603–615.
10. 10 Gamboa, C.M., Safford, M.M., Levitan, E.B., et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci 348 (2014), 108–114.
11. 11 Hoeks, S.E., Scholte op Reimer, W.J., van Gestel, Y.R., et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes 2 (2009), 338–343.
12. 12 Kern, D.M., Balu, S., Tunceli, O., Anzalone, D., Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III. Curr Med Res Opin 30 (2014), 2443–2451.
13. 13 Subherwal, S., Patel, M.R., Kober, L., et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 126 (2012), 1345–1354.
14. 14 Bitzur, R., Cohen, H., Kamari, Y., Harats, D., Intolerance to statins: mechanisms and management. Diabetes Care 36:suppl 2 (2013), S325–S330.
15. 15 Guyton, J.R., Bays, H.E., Grundy, S.M., Jacobson, T.A., An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 8 (2014), S72–S81.
16. 16 Bruckert, E., Hayem, G., Dejager, S., Yau, C., Begaud, B., Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 19 (2005), 403–414.
17. 17 Buettner, C., Davis, R.B., Leveille, S.G., Mittleman, M.A., Mukamal, K.J., Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 23 (2008), 1182–1186.
18. 18 Cohen, J.D., Brinton, E.A., Ito, M.K., Jacobson, T.A., Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6 (2012), 208–215.
19. 19 El-Salem, K., Ababneh, B., Rudnicki, S., et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 44 (2011), 877–881.
20. 20 Nichols, G.A., Koro, C.E., Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 29 (2007), 1761–1770.
21. 21 Parker, B.A., Capizzi, J.A., Grimaldi, A.S., et al. Effect of statins on skeletal muscle function. Circulation 127 (2013), 96–103.
22. 22 Zhang, H., Plutzky, J., Skentzos, S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 158 (2013), 526–534.
23. 23 American College of Cardiology Statin Intolerance App [mobile application]. American College of Cardiology website http://www.acc.org/StatinIntoleranceApp. Accessed August 22, 2016.
24. 24 Banach, M., Rizzo, M., Toth, P.P., et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11 (2015), 1–23.
25. 25 Jacobson, T.A., NLA Task Force on Statin Safety–2014 update. J Clin Lipidol 8 (2014), S1–S4.
26. 26 Mancini, G.B., Baker, S., Bergeron, J., et al. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). The Can J Cardiol 32 (2016), S35–S65.
27. 27 Rosenson, R.S., Baker, S.K., Jacobson, T.A., et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S58–S71.
28. 28 Sharrett, A.R., Ballantyne, C.M., Coady, S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001), 1108–1113.
29. 29 Classifications of diseases, functioning, and disability. Centers for Disease Control and Prevention website http://www.cdc.gov/nchs/icd/icd9cm.htm. Updated June 19, 2013. Accessed August 22, 2016.
30. 30 Rosenbaum, P.R., Optimal Matching for Observational Studies. J Amer Statist Assoc 84 (1989), 1024–1032.
31. 31 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002), 3143–3421.
32. 32 Mampuya, W.M., Frid, D., Rocco, M., et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 166 (2013), 597–603.
33. 33 Backes, J.M., Venero, C.V., Gibson, C.A., et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 42 (2008), 341–346.
34. 34 Juszczyk, M.A., Seip, R.L., Thompson, P.D., Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol 8 (2005), 197–199.
35. 35 Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol 9 (2015), 129–169.
36. 36 Rodriguez, F., Olufade, T., Heithoff, K., Friedman, H.S., Navaratnam, P., Foody, J.M., Frequency of high-risk patients not receiving high-potency statin (from a large managed care database). Am J Cardiol 115 (2015), 190–195.
37. 37 Chi, M.D., Vansomphone, S.S., Liu, I.-L.A., et al. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care 20 (2014), e105–e112.
38. 38 Wong, N.D., Young, D., Zhao, Y., et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol 10 (2016), 1109–1118.
39. 39 Tattersall, M.C., Gangnon, R.E., Karmali, K.N., Cullen, M.W., Stein, J.H., Keevil, J.G., Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys. PLoS One, 8, 2013, e59309.
40. 40 Daskalopoulou, S.S., Delaney, J.A., Filion, K.B., Brophy, J.M., Mayo, N.E., Suissa, S., Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 29 (2008), 2083–2091.
41. 41 Gomez Sandoval, Y.H., Braganza, M.V., Daskalopoulou, S.S., Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des 17 (2011), 3669–3689.
42. 42 Rasmussen, J.N., Chong, A., Alter, D.A., Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297 (2007), 177–186.
43. 43 Tziomalos, K., Athyros, V.G., Mikhailidis, D.P., Statin discontinuation: an underestimated risk [editorial]?. Curr Med Res Opin 24 (2008), 3059–3062.
44. 44 Bozovich, M., Rubino, C.M., Edmunds, J., Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 20 (2000), 1375–1383.
45. 45 Mazzolini, T.A., Irons, B.K., Schell, E.C., Seifert, C.F., Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers. J Manag Care Pharm 11 (2005), 763–771.
46. 46 Gavish, D., Leibovitz, E., Elly, I., Shargorodsky, M., Zimlichman, R., Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients. Isr Med Assoc J 4 (2002), 694–697.
47. 47 Slinin, Y., Guo, H., Li, S., et al. Association of provider-patient visit frequency and patient outcomes on hemodialysis. J Am Soc Nephrol 23 (2012), 1560–1567.
48. 48 Shin, D.W., Cho, J., Yang, H.K., et al. Impact of continuity of care on mortality and health care costs: a nationwide cohort study in Korea. Ann Fam Med 12 (2014), 534–541.
49. 49 Cho, K.H., Kim, Y.S., Nam, C.M., et al. The Association between Continuity of Care and All-Cause Mortality in Patients with Newly Diagnosed Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study, 2005-2012. PLoS One, 10, 2015, e0141465.
50. 50 Lin, I., Sung, J., Sanchez, R.J., et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm 22 (2016), 685–698.
51. 51 Jacobson, T., Edelman, S., Davidson, M., et al. Development and content validation of a patient-reported outcome measure to evaluate statin intolerance in the real world. [abstract] Value Health, 19, 2016, A52.
52. 52 Ahmad, Z., Statin intolerance. Am J Cardiol 113 (2014), 1765–1771.